Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

155
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
155
Birth Control Methods01:22

Birth Control Methods

7.4K
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
7.4K
Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

195
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
195
Ovarian Cycle01:27

Ovarian Cycle

5.8K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
5.8K
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

2.5K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
2.5K
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

7.9K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Region-based morphometry in Parkinson's disease patients with GBA mutation and its predictive role for cognition after STN-DBS.

Parkinsonism & related disorders·2026
Same author

Universal distributed blind quantum computing with solid-state qubits.

Science (New York, N.Y.)·2025
Same author

Using strain to uncover the interplay between two- and three-dimensional charge density waves in high-temperature superconducting YBa<sub>2</sub>Cu<sub>3</sub>O<sub>y</sub>.

Nature communications·2024
Same author

Real-world analysis of teclistamab in 123 RRMM patients from Germany.

Leukemia·2024
Same author

[Dysphagia in Parkinsonian Syndromes].

Der Nervenarzt·2023
Same author

Soft-Phonon and Charge-Density-Wave Formation in Nematic BaNi_{2}As_{2}.

Physical review letters·2022

Related Experiment Video

Updated: Apr 20, 2026

Author Spotlight: Advancing Primatology Through Germ Cell Research and Genetic Modification Techniques
06:17

Author Spotlight: Advancing Primatology Through Germ Cell Research and Genetic Modification Techniques

Published on: July 5, 2024

2.1K

A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter,

D Gruber1, A Skřivánek2, M Serrani3

  • 1University Clinic, General Hospital Vienna, Department of Gynecological Endocrinology and Reproductive Medicine, Vienna, Austria.

Contraception
|December 3, 2014
PubMed
Summary

This study compared two contraceptive patches. The ethinyl estradiol/gestodene (EE/GSD) patch showed improved bleeding control in the second reference period compared to the ethinyl estradiol/norelgestromin (EE/NGMN) patch.

Keywords:
Bleeding patternCycle controlEthinyl estradiolGestodeneTolerabilityTransdermal contraceptive patch

More Related Videos

Rodent Estrous Cycle Monitoring Utilizing Vaginal Lavage: No Such Thing As a Normal Cycle
09:05

Rodent Estrous Cycle Monitoring Utilizing Vaginal Lavage: No Such Thing As a Normal Cycle

Published on: August 30, 2021

9.0K
Auricular Point Acupressure Therapy: A Safe and Effective Treatment for Postsurgical Abortion Recovery
07:02

Auricular Point Acupressure Therapy: A Safe and Effective Treatment for Postsurgical Abortion Recovery

Published on: February 3, 2026

179

Related Experiment Videos

Last Updated: Apr 20, 2026

Author Spotlight: Advancing Primatology Through Germ Cell Research and Genetic Modification Techniques
06:17

Author Spotlight: Advancing Primatology Through Germ Cell Research and Genetic Modification Techniques

Published on: July 5, 2024

2.1K
Rodent Estrous Cycle Monitoring Utilizing Vaginal Lavage: No Such Thing As a Normal Cycle
09:05

Rodent Estrous Cycle Monitoring Utilizing Vaginal Lavage: No Such Thing As a Normal Cycle

Published on: August 30, 2021

9.0K
Auricular Point Acupressure Therapy: A Safe and Effective Treatment for Postsurgical Abortion Recovery
07:02

Auricular Point Acupressure Therapy: A Safe and Effective Treatment for Postsurgical Abortion Recovery

Published on: February 3, 2026

179

Area of Science:

  • Reproductive medicine
  • Contraception
  • Endocrinology

Background:

  • Transdermal contraceptive patches offer a non-daily administration route for hormonal contraception.
  • Understanding bleeding patterns and cycle control is crucial for user adherence and satisfaction with contraceptive methods.

Purpose of the Study:

  • To compare the bleeding patterns and cycle control of a novel ethinyl estradiol/gestodene (EE/GSD) contraceptive patch against an established ethinyl estradiol/norelgestromin (EE/NGMN) patch.
  • To evaluate parameters such as bleeding/spotting days, episode frequency, and duration, as well as withdrawal bleeding characteristics.

Main Methods:

  • A phase III, open-label, randomized, parallel-group trial involving healthy women aged 18-35 years.
  • Participants received either the EE/GSD patch (n=200) or the EE/NGMN patch (n=198) for seven 28-day cycles (3 weeks on, 1 week off).
  • Bleeding control was assessed over two 90-day reference periods.

Main Results:

  • While the mean number of bleeding/spotting days was comparable in the first reference period, the EE/GSD patch group showed significantly fewer bleeding/spotting days in the second reference period (15.7 vs. 18.4 days; p<0.0001).
  • Bleeding/spotting episodes were shorter with the EE/GSD patch in both reference periods (p<0.05 and p=0.0001, respectively).
  • The duration of withdrawal bleeding episodes was consistently shorter with the EE/GSD patch across all seven cycles (p<0.01), with no significant differences in intracyclic bleeding.

Conclusions:

  • The ethinyl estradiol/gestodene (EE/GSD) contraceptive patch demonstrates comparable or improved bleeding control compared to the ethinyl estradiol/norelgestromin (EE/NGMN) patch.
  • The EE/GSD patch offers a potentially favorable bleeding profile, characterized by fewer bleeding/spotting days and shorter withdrawal bleeding episodes.
  • These findings suggest the EE/GSD patch is a viable option for women seeking effective contraception with predictable cycle control.